美股異動 | 摯文集團飆漲37% 三季度淨營收超預期
格隆匯12月8日丨摯文集團9MOMO.US)盤中一度漲37.14%,報7.2美元,總市值14億美元。摯文集團公佈了2022年第三季度未經審計的財務業績。摯文集團淨營收達32.33億元,超出華爾街預期的31.341億元。不按照美國通用會計準則計量,歸屬於摯文集團的淨利潤為5.358億元,持續31個季度盈利。摯文集團董事長兼CEO唐巖表示:“我很高興能重返CEO職位。第三季度,在產品和運營的共同努力下,我們取得了不錯的財務成績和業務進展。業務方面的進展,加上提高成本效率方面的努力,使我們的利潤環比大幅增長。我為團隊在如此具有挑戰性的環境中表現出的執行能力感到非常自豪。”

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.